Orbimed Advisors Llc - Net Worth and Insider Trading
Orbimed Advisors Llc Net Worth
The estimated net worth of Orbimed Advisors Llc is at least $3.5 Billion dollars as of 2024-04-27. Orbimed Advisors Llc is the Director, 10% Owner of Synthorx Inc and owns about 5,316,355 shares of Synthorx Inc (THOR) stock worth over $361 Million. Orbimed Advisors Llc is the Director, 10% Owner of Prevail Therapeutics Inc and owns about 13,822,463 shares of Prevail Therapeutics Inc (PRVL) stock worth over $318 Million. Orbimed Advisors Llc is also the 10% Owner of SpringWorks Therapeutics Inc and owns about 5,599,842 shares of SpringWorks Therapeutics Inc (SWTX) stock worth over $255 Million. Besides these, Orbimed Advisors Llc also holds Edgewise Therapeutics Inc (EWTX) , Loxo Oncology Inc (LOXO) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , NxStage Medical Inc (NXTM) , ARS Pharmaceuticals Inc (SPRY) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Keros Therapeutics Inc (KROS) , Pacira BioSciences Inc (PCRX) , Third Harmonic Bio Inc (THRD) , Verona Pharma PLC (VRNA) , Intellia Therapeutics Inc (NTLA) , Silverback Therapeutics Inc (SBTX) , NeuroPace Inc (NPCE) , Prelude Therapeutics Inc (PRLD) , Terns Pharmaceuticals Inc (TERN) , Dimension Therapeutics Inc (DMTX) , Compass Therapeutics Inc (CMPX) , Imara Inc (IMRA) , scPharmaceuticals Inc (SCPH) , ArriVent BioPharma Inc (AVBP) , CalciMedica Inc (CALC) , Intercept Pharmaceuticals Inc (ICPT) , Adicet Bio Inc (ACET) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , 89bio Inc (ETNB) , SI-BONE Inc (SIBN) , Constellation Pharmaceuticals Inc (CNST) , TELA Bio Inc (TELA) , PMV Pharmaceuticals Inc (PMVP) , Janux Therapeutics Inc (JANX) , Passage Bio Inc (PASG) , Corvus Pharmaceuticals Inc (CRVS) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Acutus Medical Inc (AFIB) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Inspire Medical Systems Inc (INSP) , Repare Therapeutics Inc (RPTX) , Ikena Oncology Inc (IKNA) , Sientra Inc (SIENQ) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) . Details can be seen in Orbimed Advisors Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Orbimed Advisors Llc has not made any transactions after 2024-04-24 and currently still holds the listed stock(s).
Transaction Summary of Orbimed Advisors Llc
Orbimed Advisors Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Orbimed Advisors Llc owns 92 companies in total, including Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , and LogicBio Therapeutics Inc (LOGC) among others .
Click here to see the complete history of Orbimed Advisors Llc’s form 4 insider trades.
Insider Ownership Summary of Orbimed Advisors Llc
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ARQT | Arcutis Biotherapeutics Inc | 2022-06-24 | director & 10 percent owner |
XTNT | Xtant Medical Holdings Inc | 2018-02-14 | 10 percent owner |
LOGC | LogicBio Therapeutics Inc | 2020-10-01 | director & 10 percent owner |
CALC | CalciMedica Inc | 2020-09-25 | director & 10 percent owner |
PRLD | Prelude Therapeutics Inc | 2023-05-22 | director & 10 percent owner |
PMVP | PMV Pharmaceuticals Inc | 2023-11-22 | 10 percent owner |
ETNB | 89bio Inc | 2022-01-26 | director & 10 percent owner |
INSP | Inspire Medical Systems Inc | 2020-08-18 | director |
AFIB | Acutus Medical Inc | 2021-07-19 | director & 10 percent owner |
PAND | Pandion Therapeutics Inc | 2020-07-16 | 10 percent owner |
FUSN | Fusion Pharmaceuticals Inc | 2020-06-30 | director |
RPTX | Repare Therapeutics Inc | 2021-09-07 | director |
SCPH | scPharmaceuticals Inc | 2022-11-25 | 10 percent owner |
ORIC | ORIC Pharmaceuticals Inc | 2021-03-30 | director |
ALEC | Alector Inc | 2020-04-16 | 10 percent owner |
KROS | Keros Therapeutics Inc | 2020-04-13 | director |
IMRA | Imara Inc | 2021-07-16 | director & 10 percent owner |
CTIC | CTI BioPharma Corp | 2021-01-07 | 10 percent owner |
PASG | Passage Bio Inc | 2023-06-28 | 10 percent owner |
SRRA | Sierra Oncology Inc | 2019-11-22 | director & 10 percent owner |
TCDAQ | Tricida Inc | 2022-11-25 | director & 10 percent owner |
TELA | TELA Bio Inc | 2023-04-21 | 10 percent owner |
SWTX | SpringWorks Therapeutics Inc | 2022-09-12 | 10 percent owner |
CRVS | Corvus Pharmaceuticals Inc | 2021-09-20 | director |
PRVL | Prevail Therapeutics Inc | 2019-06-24 | director & 10 percent owner |
PRNB | Principia Biopharma Inc | 2019-05-21 | 10 percent owner |
NXTC | NextCure Inc | 2019-05-13 | director & 10 percent owner |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | director |
AVDR | Avedro Inc | 2019-02-19 | 10 percent owner |
ALPN | Alpine Immune Sciences Inc | 2023-12-28 | director |
THOR | Synthorx Inc | 2018-12-11 | director & 10 percent owner |
SIBN | SI-BONE Inc | 2018-10-19 | director |
GH | Guardant Health Inc | 2018-10-03 | 10 percent owner |
ARVN | Arvinas Inc | 2018-09-26 | 10 percent owner |
STDY | SteadyMed Ltd | 2018-08-30 | 10 percent owner |
VRAYQ | ViewRay Inc | 2018-08-20 | director & 10 percent owner |
CNST | Constellation Pharmaceuticals Inc | 2018-07-23 | 10 percent owner |
CRNX | Crinetics Pharmaceuticals Inc | 2018-07-17 | 10 percent owner |
ARPO | Aerpio Pharmaceuticals Inc | 2020-12-08 | director & 10 percent owner |
ARMO | ARMO BioSciences Inc | 2018-06-22 | director & 10 percent owner |
ADAP | Adaptimmune Therapeutics PLC | 2018-06-06 | director |
RYTM | Rhythm Pharmaceuticals Inc | 2018-05-22 | 10 percent owner |
PIRS | Pieris Pharmaceuticals Inc | 2018-04-30 | director & 10 percent owner |
BOLD | Audentes Therapeutics Inc | 2018-03-12 | 10 percent owner |
GKOS | Glaukos Corp | 2018-03-06 | director |
KALA | Kala Bio Inc | 2018-02-08 | 10 percent owner & other: See Remarks |
SYBX | Synlogic Inc | 2017-08-28 | director |
LOXO | Loxo Oncology Inc | 2017-12-08 | director |
XFOR | X4 Pharmaceuticals Inc | 2017-11-15 | 10 percent owner |
ROKA | Sorrento Tech Inc | 2017-10-03 | 10 percent owner |
SYRE | Spyre Therapeutics Inc | 2017-02-21 | 10 percent owner |
NBRVF | Nabriva Therapeutics PLC | 2016-12-30 | director & 10 percent owner |
RPBIF | Response Biomedical Corp | 2016-11-29 | director & 10 percent owner |
RLYP | Relypsa Inc | 2016-07-25 | 10 percent owner |
RNAC | Cartesian Therapeutics Inc | 2016-06-27 | director & 10 percent owner |
NTLA | Intellia Therapeutics Inc | 2016-05-11 | 10 percent owner |
OTIC | Otonomy Inc | 2015-11-30 | director |
DMTX | Dimension Therapeutics Inc | 2015-10-27 | director & 10 percent owner |
SIENQ | Sientra Inc | 2015-10-12 | 10 percent owner |
ICPT | Intercept Pharmaceuticals Inc | 2015-03-26 | director & 10 percent owner |
MRTX | Mirati Therapeutics Inc | 2014-07-01 | 10 percent owner |
XLRN | Acceleron Pharma Inc | 2013-09-24 | other: Former 10% Owner |
SUPN | Supernus Pharmaceuticals Inc | 2013-02-13 | 10 percent owner |
ANTH | Anthera Pharmaceuticals Inc | 2013-01-30 | director |
AMRN | Amarin Corp PLC | 2011-01-01 | director & 10 percent owner |
PCRX | Pacira BioSciences Inc | 2012-03-12 | 10 percent owner |
CCXI | ChemoCentryx Inc | 2012-02-08 | 10 percent owner |
ATHXQ | Athersys Inc | 2011-04-26 | director & other: (1) |
NXTM | NxStage Medical Inc | 2010-12-09 | director |
KURU | Kun Run Biotechnology Inc | 2010-04-30 | 10 percent owner |
ALBO | Albireo Pharma Inc | 2007-05-10 | 10 percent owner |
ARYX | ARYx Therapeutics Inc | 2009-05-22 | 10 percent owner |
PODD | Insulet Corp | 2007-05-14 | director |
AADI | Aadi Bioscience Inc | 2017-03-15 | director & 10 percent owner |
NPCE | NeuroPace Inc | 2024-04-23 | 10 percent owner |
DBTX | Decibel Therapeutics Inc | 2021-02-17 | 10 percent owner |
VRNA | Verona Pharma PLC | 2023-05-15 | director & 10 percent owner |
SBTX | Silverback Therapeutics Inc | 2020-12-08 | director & 10 percent owner |
EWTX | Edgewise Therapeutics Inc | 2024-01-23 | director & 10 percent owner |
ACET | Adicet Bio Inc | 2024-01-25 | director & 10 percent owner |
CMPX | Compass Therapeutics Inc | 2022-11-08 | director & 10 percent owner |
THRX | Theseus Pharmaceuticals Inc | 2023-07-17 | director & 10 percent owner |
KNTE | Kinnate Biopharma Inc | 2023-05-05 | director |
GLTO | Galecto Inc | 2023-08-15 | director & 10 percent owner |
IRON | Disc Medicine Inc | 2023-12-18 | director & 10 percent owner |
JANX | Janux Therapeutics Inc | 2021-12-29 | director |
TERN | Terns Pharmaceuticals Inc | 2022-12-23 | director & 10 percent owner |
IKNA | Ikena Oncology Inc | 2021-03-30 | director |
THRD | Third Harmonic Bio Inc | 2022-09-19 | director & 10 percent owner |
SPRY | ARS Pharmaceuticals Inc | 2023-08-29 | director |
ELVN | Enliven Therapeutics Inc | 2020-03-11 | director & 10 percent owner |
TSBX | Turnstone Biologics Corp | 2023-07-20 | director & 10 percent owner |
Orbimed Advisors Llc Latest Holdings Summary
Orbimed Advisors Llc currently owns a total of 74 stocks. Among these stocks, Orbimed Advisors Llc owns 5,316,355 shares of Synthorx Inc (THOR) as of December 11, 2018, with a value of $361 Million and a weighting of 10.25%. Orbimed Advisors Llc owns 13,822,463 shares of Prevail Therapeutics Inc (PRVL) as of June 24, 2019, with a value of $318 Million and a weighting of 9.01%. Orbimed Advisors Llc also owns 5,599,842 shares of SpringWorks Therapeutics Inc (SWTX) as of September 12, 2022, with a value of $255 Million and a weighting of 7.23%. The other 71 stocks Edgewise Therapeutics Inc (EWTX) , Loxo Oncology Inc (LOXO) , Audentes Therapeutics Inc (BOLD) , Principia Biopharma Inc (PRNB) , Turning Point Therapeutics Inc (TPTX) , Relypsa Inc (RLYP) , Rhythm Pharmaceuticals Inc (RYTM) , Supernus Pharmaceuticals Inc (SUPN) , NxStage Medical Inc (NXTM) , ARS Pharmaceuticals Inc (SPRY) , Theseus Pharmaceuticals Inc (THRX) , Mirati Therapeutics Inc (MRTX) , CTI BioPharma Corp (CTIC) , Fusion Pharmaceuticals Inc (FUSN) , Keros Therapeutics Inc (KROS) , Pacira BioSciences Inc (PCRX) , Third Harmonic Bio Inc (THRD) , Verona Pharma PLC (VRNA) , Intellia Therapeutics Inc (NTLA) , Silverback Therapeutics Inc (SBTX) , NeuroPace Inc (NPCE) , Prelude Therapeutics Inc (PRLD) , Terns Pharmaceuticals Inc (TERN) , Dimension Therapeutics Inc (DMTX) , Compass Therapeutics Inc (CMPX) , Imara Inc (IMRA) , scPharmaceuticals Inc (SCPH) , ArriVent BioPharma Inc (AVBP) , CalciMedica Inc (CALC) , Intercept Pharmaceuticals Inc (ICPT) , Adicet Bio Inc (ACET) , ORIC Pharmaceuticals Inc (ORIC) , Alpine Immune Sciences Inc (ALPN) , 89bio Inc (ETNB) , SI-BONE Inc (SIBN) , Constellation Pharmaceuticals Inc (CNST) , TELA Bio Inc (TELA) , PMV Pharmaceuticals Inc (PMVP) , Janux Therapeutics Inc (JANX) , Passage Bio Inc (PASG) , Corvus Pharmaceuticals Inc (CRVS) , Alector Inc (ALEC) , Turnstone Biologics Corp (TSBX) , Disc Medicine Inc (IRON) , Adaptimmune Therapeutics PLC (ADAP) , Decibel Therapeutics Inc (DBTX) , NextCure Inc (NXTC) , Arcutis Biotherapeutics Inc (ARQT) , Xtant Medical Holdings Inc (XTNT) , Spyre Therapeutics Inc (SYRE) , resTORbio Inc (TORC) , Cartesian Therapeutics Inc (RNAC) , Kinnate Biopharma Inc (KNTE) , Acutus Medical Inc (AFIB) , Galecto Inc (GLTO) , Aerpio Pharmaceuticals Inc (ARPO) , LogicBio Therapeutics Inc (LOGC) , Kala Bio Inc (KALA) , Inspire Medical Systems Inc (INSP) , Repare Therapeutics Inc (RPTX) , Ikena Oncology Inc (IKNA) , Sientra Inc (SIENQ) , Otonomy Inc (OTIC) , Pieris Pharmaceuticals Inc (PIRS) , ViewRay Inc (VRAYQ) , Logic Devices Inc (LOGC) , Athersys Inc (ATHXQ) , Sorrento Tech Inc (ROKA) , SteadyMed Ltd (STDY) , Glaukos Corp (GKOS) , Tricida Inc (TCDAQ) have a combined weighting of 73.52% among all his current holdings.
Latest Holdings of Orbimed Advisors Llc
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
THOR | Synthorx Inc | 2018-12-11 | 5,316,355 | 67.99 | 361,458,976 |
PRVL | Prevail Therapeutics Inc | 2019-06-24 | 13,822,463 | 23.00 | 317,916,649 |
SWTX | SpringWorks Therapeutics Inc | 2022-09-12 | 5,599,842 | 45.53 | 254,960,806 |
EWTX | Edgewise Therapeutics Inc | 2024-01-23 | 14,756,096 | 16.17 | 238,606,072 |
LOXO | Loxo Oncology Inc | 2017-12-08 | 941,000 | 234.66 | 220,815,060 |
BOLD | Audentes Therapeutics Inc | 2018-03-12 | 3,539,997 | 59.97 | 212,293,620 |
PRNB | Principia Biopharma Inc | 2019-05-21 | 1,605,713 | 100.05 | 160,651,586 |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | 2,027,550 | 76.01 | 154,114,076 |
RLYP | Relypsa Inc | 2016-07-25 | 3,356,400 | 31.99 | 107,371,236 |
RYTM | Rhythm Pharmaceuticals Inc | 2018-05-22 | 2,750,079 | 38.28 | 105,273,024 |
SUPN | Supernus Pharmaceuticals Inc | 2013-02-13 | 3,000,000 | 30.07 | 90,210,000 |
NXTM | NxStage Medical Inc | 2010-12-09 | 2,690,476 | 30.00 | 80,714,280 |
SPRY | ARS Pharmaceuticals Inc | 2023-08-29 | 9,240,887 | 8.35 | 77,161,406 |
THRX | Theseus Pharmaceuticals Inc | 2023-07-17 | 17,713,600 | 4.06 | 71,917,216 |
MRTX | Mirati Therapeutics Inc | 2014-07-01 | 1,167,000 | 58.70 | 68,502,900 |
CTIC | CTI BioPharma Corp | 2021-01-07 | 7,520,600 | 9.09 | 68,362,254 |
FUSN | Fusion Pharmaceuticals Inc | 2020-06-30 | 3,122,770 | 21.42 | 66,889,733 |
KROS | Keros Therapeutics Inc | 2020-04-13 | 1,119,812 | 57.86 | 64,792,322 |
PCRX | Pacira BioSciences Inc | 2012-03-12 | 2,446,000 | 26.33 | 64,403,180 |
THRD | Third Harmonic Bio Inc | 2022-09-19 | 5,779,071 | 10.83 | 62,587,339 |
VRNA | Verona Pharma PLC | 2023-05-15 | 3,777,778 | 15.47 | 58,442,226 |
NTLA | Intellia Therapeutics Inc | 2016-05-11 | 2,662,180 | 20.76 | 55,266,857 |
SBTX | Silverback Therapeutics Inc | 2020-12-08 | 8,740,888 | 5.87 | 51,309,013 |
NPCE | NeuroPace Inc | 2024-04-24 | 3,435,541 | 13.39 | 46,001,894 |
PRLD | Prelude Therapeutics Inc | 2023-05-22 | 10,646,056 | 4.07 | 43,329,448 |
TERN | Terns Pharmaceuticals Inc | 2022-12-23 | 7,619,135 | 4.91 | 37,409,953 |
DMTX | Dimension Therapeutics Inc | 2015-10-27 | 5,397,698 | 5.95 | 32,116,303 |
CMPX | Compass Therapeutics Inc | 2022-11-08 | 18,791,422 | 1.45 | 27,247,562 |
IMRA | Imara Inc | 2021-07-16 | 4,199,068 | 6.32 | 26,538,110 |
SCPH | scPharmaceuticals Inc | 2022-11-25 | 5,559,528 | 4.49 | 24,962,281 |
AVBP | ArriVent BioPharma Inc | 2024-01-30 | 1,513,664 | 15.44 | 23,370,972 |
CALC | CalciMedica Inc | 2020-09-25 | 4,163,347 | 5.45 | 22,690,241 |
ICPT | Intercept Pharmaceuticals Inc | 2015-03-26 | 1,120,324 | 19.00 | 21,286,156 |
ACET | Adicet Bio Inc | 2024-01-25 | 11,447,140 | 1.68 | 19,231,195 |
ORIC | ORIC Pharmaceuticals Inc | 2021-03-30 | 2,212,571 | 8.07 | 17,855,448 |
ALPN | Alpine Immune Sciences Inc | 2023-12-28 | 264,315 | 64.56 | 17,064,176 |
ETNB | 89bio Inc | 2022-01-26 | 1,829,436 | 8.26 | 15,111,141 |
SIBN | SI-BONE Inc | 2018-10-19 | 985,368 | 14.57 | 14,356,812 |
CNST | Constellation Pharmaceuticals Inc | 2018-07-23 | 417,921 | 33.99 | 14,205,135 |
TELA | TELA Bio Inc | 2023-04-21 | 2,835,542 | 4.45 | 12,618,162 |
PMVP | PMV Pharmaceuticals Inc | 2023-11-22 | 6,475,291 | 1.75 | 11,331,759 |
JANX | Janux Therapeutics Inc | 2021-12-29 | 231,098 | 47.39 | 10,951,734 |
PASG | Passage Bio Inc | 2023-06-28 | 8,034,000 | 1.32 | 10,604,880 |
CRVS | Corvus Pharmaceuticals Inc | 2021-09-20 | 6,943,654 | 1.45 | 10,068,298 |
ALEC | Alector Inc | 2020-04-16 | 1,906,718 | 5.25 | 10,010,270 |
TSBX | Turnstone Biologics Corp | 2023-07-20 | 3,099,265 | 2.76 | 8,553,971 |
IRON | Disc Medicine Inc | 2023-12-18 | 224,405 | 27.55 | 6,182,358 |
ADAP | Adaptimmune Therapeutics PLC | 2018-06-06 | 4,901,310 | 1.08 | 5,268,908 |
DBTX | Decibel Therapeutics Inc | 2021-02-17 | 883,418 | 4.91 | 4,337,582 |
NXTC | NextCure Inc | 2019-05-13 | 2,711,013 | 1.35 | 3,659,868 |
ARQT | Arcutis Biotherapeutics Inc | 2022-06-24 | 415,142 | 8.47 | 3,516,253 |
XTNT | Xtant Medical Holdings Inc | 2018-02-14 | 3,316,128 | 0.95 | 3,150,322 |
SYRE | Spyre Therapeutics Inc | 2017-02-21 | 58,781 | 33.56 | 1,972,690 |
TORC | resTORbio Inc | 2018-01-30 | 690,055 | 2.28 | 1,573,325 |
RNAC | Cartesian Therapeutics Inc | 2016-06-27 | 60,847 | 21.03 | 1,279,612 |
KNTE | Kinnate Biopharma Inc | 2023-05-05 | 450,000 | 2.65 | 1,192,500 |
AFIB | Acutus Medical Inc | 2021-07-19 | 6,553,408 | 0.17 | 1,091,142 |
GLTO | Galecto Inc | 2023-08-15 | 1,510,375 | 0.70 | 1,064,512 |
ARPO | Aerpio Pharmaceuticals Inc | 2020-12-08 | 346,265 | 2.20 | 761,783 |
LOGC | LogicBio Therapeutics Inc | 2020-10-01 | 296,296 | 2.07 | 613,333 |
KALA | Kala Bio Inc | 2018-02-08 | 68,957 | 6.30 | 434,429 |
INSP | Inspire Medical Systems Inc | 2020-08-18 | 1,784 | 237.45 | 423,611 |
RPTX | Repare Therapeutics Inc | 2021-09-07 | 96,190 | 3.20 | 307,808 |
IKNA | Ikena Oncology Inc | 2021-03-30 | 130,924 | 1.30 | 170,201 |
SIENQ | Sientra Inc | 2015-10-12 | 178,500 | 0.10 | 17,832 |
OTIC | Otonomy Inc | 2015-11-30 | 1,850,094 | 0.01 | 15,726 |
PIRS | Pieris Pharmaceuticals Inc | 2018-04-30 | 486 | 11.72 | 5,696 |
VRAYQ | ViewRay Inc | 2018-08-20 | 69,617 | 0.00 | 1 |
LOGC | Logic Devices Inc | 2018-10-23 | 6,466,783 | 0.00 | 0 |
ATHXQ | Athersys Inc | 2011-04-26 | 0 | 0.00 | 0 |
ROKA | Sorrento Tech Inc | 2017-10-03 | 0 | 0.65 | 0 |
STDY | SteadyMed Ltd | 2018-08-30 | 0 | 4.73 | 0 |
GKOS | Glaukos Corp | 2018-03-06 | 0 | 99.48 | 0 |
TCDAQ | Tricida Inc | 2022-11-25 | 0 | 0.00 | 0 |
Holding Weightings of Orbimed Advisors Llc
Orbimed Advisors Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 0 transactions in Synthorx Inc (THOR) over the past 5 years. The most-recent trade in Synthorx Inc is the acquisition of 1,363,636 shares on December 11, 2018, which cost Orbimed Advisors Llc around $15 Million.
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 1 transactions in Prevail Therapeutics Inc (PRVL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prevail Therapeutics Inc is the acquisition of 882,352 shares on June 24, 2019, which cost Orbimed Advisors Llc around $15 Million.
According to the SEC Form 4 filings, Orbimed Advisors Llc has made a total of 6 transactions in SpringWorks Therapeutics Inc (SWTX) over the past 5 years, including 1 buys and 5 sells. The most-recent trade in SpringWorks Therapeutics Inc is the sale of 153,897 shares on September 12, 2022, which brought Orbimed Advisors Llc around $5 Million.
More details on Orbimed Advisors Llc's insider transactions can be found in the Insider Trading History of Orbimed Advisors Llc table.Insider Trading History of Orbimed Advisors Llc
- 1
Orbimed Advisors Llc Trading Performance
GuruFocus tracks the stock performance after each of Orbimed Advisors Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Orbimed Advisors Llc is 9.16%. GuruFocus also compares Orbimed Advisors Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Orbimed Advisors Llc within 3 months outperforms 64 times out of 117 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Orbimed Advisors Llc's insider trading performs compared to the benchmark.
Performance of Orbimed Advisors Llc
Average Return
-2.01%
Outperforming Transactions
36%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 3.27 | 9.16 | 1.87 | -2.01 | -9.46 | -12.27 |
Relative Return to S&P 500(%) | 2.75 | 6.56 | -2.81 | -12.47 | -19.36 | -23.48 |
Orbimed Advisors Llc Ownership Network
Ownership Network List of Orbimed Advisors Llc
Ownership Network Relation of Orbimed Advisors Llc
Orbimed Advisors Llc Owned Company Details
What does Arcutis Biotherapeutics Inc do?
Who are the key executives at Arcutis Biotherapeutics Inc?
Orbimed Advisors Llc is the director & 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include director & 10 percent owner Patrick J Heron , SVP and Chief Business Officer Matthew Richard Moore , and director & President and CEO Todd Franklin Watanabe .
Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary
Over the past 18 months, Orbimed Advisors Llc made no insider transaction in Arcutis Biotherapeutics Inc (ARQT). Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 30,155 shares made by Todd Franklin Watanabe , a net sale of 37,403 shares made by Howard G. Welgus , and a net sale of 10,594 shares made by Masaru Matsuda .
In summary, during the past 3 months, insiders sold 29,378 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 21,052 shares, with a net sale of 8,326 shares. During the past 18 months, 104,916 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 2,401 shares.
Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arcutis Biotherapeutics Inc Insider Transactions
Orbimed Advisors Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Orbimed Advisors Llc. You might contact Orbimed Advisors Llc via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.